KALA
KALA BIO, Inc.NASDAQHealthcare$0.17+4.42%ClosedMarket Cap: $3.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.14
P/S
14.93
EV/EBITDA
-0.44
DCF Value
$3.33
FCF Yield
-846.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3.1%
Operating Margin
-15055.9%
Net Margin
-14110.6%
ROE
-2323.9%
ROA
-143.2%
ROIC
-179.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | NaN% | $-7.2M | $-7.6M | $-1.07 | — |
| Q2 2025 | $0.00 | -Infinity% | $-10.9M | $-11.2M | $-1.71 | — |
| Q1 2025 | $0.00 | -Infinity% | $-10.7M | $-8.9M | $-1.41 | — |
| Q4 2024 | $254.0K | 50.0% | $-9.5M | $-8.2M | $-1.74 | — |
| FY 2024 | $0.00 | -Infinity% | $-41.0M | $-38.5M | $-6.98 | — |
| Q3 2024 | $0.00 | -Infinity% | $-10.0M | $-8.9M | $-1.93 | — |
| Q2 2024 | $0.00 | -Infinity% | $-9.6M | $-9.6M | $-3.16 | — |
| Q1 2024 | $0.00 | -Infinity% | $-11.9M | $-11.8M | $-4.20 | — |
| Q4 2023 | $70.0K | -100.0% | $-9.1M | $-8.6M | $-3.18 | — |
| FY 2023 | $0.00 | -Infinity% | $-39.2M | $-42.2M | $-17.35 | — |
| Q3 2023 | $0.00 | -Infinity% | $-8.5M | $-8.7M | $-3.41 | — |
| Q2 2023 | $0.00 | -Infinity% | $-9.6M | $-10.4M | $-4.36 | — |